All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 8 November, Alessia Castellino and colleagues, published in Blood Cancer Journal the results of a long-term follow-up analysis from two phase II trials conducted by the Mayo Clinic, USA (MC078E) and the Italian Lymphoma Foundation, IT (REAL07).
The trials investigated the efficacy and safety of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) plus lenalidomide treatment in newly-diagnosed untreated patients with diffuse large B-cell lymphoma (DLBCL). Both trials reported a feasible and effective profile for R-CHOP and lenalidomide with an overall response rate (ORR) higher than 90%. The aim of this study was to report the long-term follow-up outcomes of this treatment from these two independent phase II trials. The primary endpoints of this analysis were progression-free survival (PFS), time to progression (TTP), overall survival (OS) and safety.
This long-term follow-up analysis of two phase II trials on newly-diagnosed DLBCL patients, indicates that R-CHOP21 together with lenalidomide maintain a high efficacy over the years with very good PFS, OS and ITT rates. This combination treatment seems to also be tolerable and safe up to a five-year follow-up, with a very low incidence of secondary malignancies.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox